Cancer immunology and colorectal cancer recurrence

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 4, 2011, Pages 1421-1431

  Vannucci, Luca ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

Author keywords

Anticancer Immune Response; Cancer Recurrence; Colorectal Cancer; Immunomonitoring; Inflammation; Review; Tumor Microenvironment

Indexed keywords

ARGININE; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYAMINE; PROSTAGLANDIN E2; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISTANT METASTASIS; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOMODULATION; LOCAL METASTASIS; MINIMAL RESIDUAL DISEASE; REGULATORY T LYMPHOCYTE; TUMOR ABLATION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; METASTASIS; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; STAT3 TRANSCRIPTION FACTOR;

EID: 80053117801     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s233     Document Type: Article

References (115)

1. S. Rasheed, D. M. Bowley, O. Aziz, P. P. Tekkis, A. E. Sadat, T. Guenther, M. L. Boello, P. J. McDonald, I. C. Talbot and J. M. Northover: Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. Colorectal Dis 10, 231-238 (2008)
2. F. Michelassi, L. Vannucci, J.J. Ayala, R. Chappel, R. Goldberg and G. E. Block: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 108, 787-792 (1990)
3. M. Camus, M. Tosolini, B. Mlecnik, F. Pagès, A. Kirilovsky, A. Berger, A. Costes, G. Bindea, P. Charoentong, P. Bruneval, Z. Trajanoski, W. H. Fridman and J. Galon: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69, 2685-2693 (2009)
4. M. Grimm, M. Lazariotou, S. Kircher, A. Höfelmayr, C. T. Germer, B. H. von Rahden, A. M. Waaga-Gasser and M. Gasser: Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer - indications for anti-TNF-alpha agents in cancer treatment. Anal Cell Pathol (Amst) 33, 151-163 (2010)
5. L. B. Saltz : Adjuvant therapy for colon cancer. Surg Oncol Clin N Am 19, 819-827 (2010)
6. J. D. Farrar, K. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr and N. E. Street: Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumordormant state. J Immunol 162, 2842-2849 (1999)
7. N. Müller-Hermelink, H. Braumüller, B. Pichler, T. Wieder, R. Mailhammer, K. Schaak, K. Ghoreschi, A. Yazdi, R. Haubner, C. A. Sander, R. Mocikat, M. Schwaiger, I. Förster, R. Huss, W. A. Weber, M. Kneilling and M. Rö cken: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13, 507-518 (2008)
8. C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth and R. D. Schreiber: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007)
9. R. Demicheli, M. W. Retsky, W. J. Hrushesky and M. Baum: Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4, 699-710 (2007)
10. M. Guba, G. Cernaianu, G. Koehl, E. K. Geissler, K. W. Jauch, M. Anthuber, W. Falk and M. Steinbauer: A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 61, 5575-5579 (2001)
11. R. L. Whelan, M. Franklin, S. D. Holubar, J. Donahue, R. Fowler, C. Munger, J. Doorman, J. E. Balli, J. Glass, J. J. Gonzalez, M. Bessler, H. Xie and M. Treat: Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc 17, 972-978 (2003)
12. E. Peranzoni, I. Marigo, L. Dolcetti, S. Ugel, N. Sonda,E. Taschin, B. Mantelli, V. Bronte and P. Zanovello: Role of arginine metabolism in immunity and immunopathology. Immunobiology 212, 795-812 (2007)
13. D. S. Steinbrech, M. T. Longaker, B. J. Mehrara, P. B. Saadeh, G. S. Chin, R. P. Gerrets, D. C. Chau, N. M. Rowe and G. K. Gittes: Fibroblast response to hypoxia: the relationship between angiogenesis and matrix regulation. J Surg Res 84, 127-133 (1999)
14. J. E. Rundhaug: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9, 267-285 (2005)
15. P. J. O'Dwyer: The present and future of angiogenesisdirected treatments of colorectal cancer. Oncologist 11, 992-998 (2006)
16. J. H. Donohue, S. Williams S S. Cha, H. E. Windschitl, T. E. Witzig, H. Nelson, R. J. Jr. Fitzgibbons, H. S. Wieand and C. G. Moertel: Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 13, 1671-1678 (1995)
17. M. Chiarugi, P. Buccianti, M. Disarli, C. Galatioto and E. Cavina: Effect of blood transfusions on disease-free interval after rectal cancer surgery. Hepatogastroenterology 47, 1002-1005 (2000)
18. M. Jagoditsch, P. Pozgainer, A. Klingler and J. Tschmelitsch: Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum 49, 1116-1130 (2006)
19. A. Bufalari,G. Giustozzi, M. F. Burattini, S. Servili, C. Bussotti, E. Lucaroni, E. Ricci and F. Sciannameo: Rectal cancer surgery in the elderly: a multivariate analysis of outcome risk factors. J Surg Oncol 93, 173-180 (2006)
20. K. Yoshimatsu, K. Kuhara, H. Itagaki, M. Aizawa, H. Yokomizo, T. Fujimoto, T. Otani, G. Osawa, R. Kobayashi and K. Ogawa: Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res 28, 373-378 (2008)
21. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere and G. Kroemer: The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118, 1991-2001 (2008)
22. E. Mihich: Anticancer drug-induced immunomodulation and cancer therapeutics. Curr Canc Ther Rev 3, 194-198 (2007)
23. A. M. Claessen, H. Valster, H. Bril, S. Meyer and R. J. Scheper: Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol Immunother 28, 131-135 (1989)
24. R. Kobayashi, K. Yoshimatsu, H. Yokomizo, T. Katsube and K. Ogawa: Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res 27, 675-679 (2007)
25. C. Ménard, F. Martin, L. Apetoh, F. Bouyer and F. Ghiringhelli: Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57, 1579-1587 (2008)
26. M. J. Renan: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinogenesis 7, 139-146 (1993)
27. B. Vogelstein and K. W. Kinzler: Cancer genes and the pathways they control. Nat Med 10, 789-799 (2004)
28. D. Pardoll: Does the immune system see tumors as foreign or self? Ann Rev Immunol 21, 807-839 (2003)
29. P. C. Hanawalt and A. Sarasin: Cancer prone hereditary diseases with DNA processing abnormalities. Trends Genet 2, 124-129 (1986)
30. A. Garcia-Lora, I. Algarra and F. Garrido: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195, 346-355 (2003)
31. J. Taylor-Papadimitriou, J. M. Burchell, T. Plunkett, R. Graham, I. Correa, D. Miles and M. Smith: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7, 209-221 ( 2002)
32. M. Macaluso, M. G. Paggi and A. Giordano: Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 22, 6472-6478 (2003)
33. S. C. Robinson and L. M. Coussens: Soluble mediators of inflammation during tumor development. Adv Cancer Res 93, 159-187 (2005)
34. S. Gallucci and P. Matzinger: Danger signals: SOS to the immune system. Curr Opin Immunol 13, 114-119 (2001)
35. M. J. Bissell, P. A. Kenny and D. C. Radisky. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70, 343-356 (2005)
36. C. J. Malemud: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11, 1696-1701 (2006)
37. N. A. Bhowmick and H. L. Moses: Tumor-stroma interactions. Curr Opin Genet Dev 15, 97-101 (2005)
38. P. Kaler, L. Augenlicht and L. Klampfer: Macrophagederived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 28, 3892-3902 (2009)
39. L. S. Angelo and R. Kurzrock: Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13, 2825-2830 (2007)
40. C. M. Nelson and M. J. Bissell. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22, 287-309 (2006)
41. A. Albini and M. B. Sporn: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7, 139-147 (2007)
42. D. Hanahan and R. A. Weingerg: The hallmarks of cancer. Cell 100, 57-70 (2000)
43. G.P. Dunn, L. J. Old and R. D. Schreiber: The three Es of cancer immunoediting. Annu Rev Immunol 22, 329-360 (2004)
44. L. Zitvogel, A. Tesniere and G. Kroemer: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715-727 (2006)
45. G. A. Rabinovich and M. A. Toscano. Turning 'sweet ' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 9, 338-352 (2009)
46. S. I. Hakomori: Inaugural article: the glycosynapse. Proc Natl Acad Sci USA 99, 225-232 (2002)
47. I. Brockhausen: Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 7, 599-604 (2006)
48. J. W. Dennis, M. Granovsky and C. E. Warren: Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1473, 21-34 (1999)
49. E. Gorelik, U. Galili and A. Raz: On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev 20, 245-277 (2001)
50. N. Taniguchi, S. K. Jan, M. Takahashi, J. O. Ko, K. Sasai, E. Miyoshi and Y. Ikeda: Glycosyltransferases: cell surface remodeling and regulation of receptor tyrosine kinases-induced signaling. Pure Appl Chem 71, 719-728 (1999)
51. R. Nakay, S. Miyagawa, K. Matsunami, M. Yamada, M. Koma, N. Taniguchi and R. Shirakura: Effect of the remodeling of a glycoantigen on natural killer cell-mediated direct cytotoxicity. Transplant Proc 32, 929-930 (2000)
52. T. Koike, N. Kimura, K. Miyazaki, T. Yabuta, K. Kumamoto, S. Takenoshita, J. Chen, M. Kobayashi, M. Hosokawa, A. Taniguchi, T. Kojima, N. Ishida, M. Kawakita, H. Yamamoto, H. Takematsu, A. Suzuki, Y. Kozutsumi and R. Kannagi: Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 101, 8132-8137 (2004)
53. M. Pospisil, K. Bezouska, M. Campa, A. Fiserova, J. Kubrycht, N. Huan, S. Chan and G. Trinchieri: Mechanisms of NK recognition and activation based on lectin-saccharide interactions. Adv Exp Med Biol 371A, 307-311 (1995)
54. M. Pospíšil, J. Kubrycht, K. Bezouška, O. Táborský, M. Novák M and J. Kocourek: Lactosamine type asialooligosaccharide recognition in NK cytotoxicity. Immunol Lett 12, 83-90 (1986)
55. L. Vannucci, A. Fiserova, O. Horvath, P. Rossmann, F. Mosca and M. Pospisil: Cancer evolution and immunity in a rat colorectal carcinogenesis model. Int J Oncol 25, 973-981 (2004)
56. R. Somasundaram, L. Jacob, R. Swoboda, L. Caputo, H. Song, S. Basak, D. Monos, D. Peritt, F. Marincola, D. Cai, B. Birebent, E. Bloome, J. Kim, K. Berencsi, M. Mastrangelo and D. Herlyn: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62, 5267-5272 (2002)
57. A. G. Menon, C. M. Janssen-van Rhijn, H. Morreau, H. Putter, R. A. Tollenaar, C. J. van de Velde, G. J. Fleuren and P. J. Kuppen: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84, 493-501 (2004)
58. M. J. Smyth, G. P. Dunn and R. D. Schreiber: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90, 1-50 (2006)
59. A. Hayday and R. Tigelaar: Immunoregulation in the tissues by γδT cells. Nature Rev Immunol 3, 233-242 (2003)
60. R. R. Brutkiewicz and V. Sriram: Natural killer T (NKT) cells and their role in antitumor immunity. Critical Reviews in Oncology/Hematology 41, 287-298 (2002)
61. D. Peritt, S. Robertson, G. Gri, L. Showe, M. Aste- Amezaga and G. Trinchieri: Cutting edge: differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 161, 5821-5824 (1998)
62. I. Kryczek, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang and W. Zou: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178, 6730-6733 (2007)
63. C. W. Chan and F. Housseau: The 'kiss of death ' by dendritic cells to cancer cells. Cell Death Differ 15, 58-69 (2008)
64. X. Z. Ye, S. C. Yu and X. W. Bian: Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 37, 423-430 (2010)
65. G. Pawelec: Tumor escape: antitumor effectors too much of a good thing? Cancer Immunol Immunother 53, 262-274 (2003)
66. F. O. Martinez, A. Sica, A. Mantovani and M. Locati: M acrophage activation and polarization. Front Biosci 13, 453-461 (2008)
67. S. E. Erdman and T. Poutahidis: Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 38, 76-87 (2010)
68. P. Allavena, A. Sica, C. Garlanda and A. Mantovani: The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222, 155-161 (2008)
69. F. Balkwill and A. Mantovani: Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001)
70. H. F. Dvorak: Tumors: wounds that not heal. New Engl J Med 315, 1650-1659 (1986)
71. F. R. Greten, L. Eckmann, T. F. Greten, J. M. Park, Z. W. Li, L. J. Egan, M. F. Kagnoff and M. Karin: IKK-beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004)
72. M. Karin: Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006)
73. J. L. Luo, S. Maeda, L. C. Hsu, H. Yagita and M. Karin: Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305 (2004)
74. L. Yang and Z. Pei: Bacteria, inflammation, and colon cancer. World J Gastroenterol 12, 6741-6746 (2006)
75. A. J. Schottelius and H. Dinter: Cytokines, NFkappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130, 67-87 (2006)
76. S. P. Hussain, L. J. Hofseth and C. C. Harris: Radical causes of cancer. Nat Rev Cancer 3, 276-285 (2003)
77. N. W. Zwirner, M. B. Fuertes, M. V. Girart, C. I. Domaica and L. E. Rossi: Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICANKG2D system. Cytokine Growth Factor Rev 18, 159-170 (2007)
78. J. G. Sinkovics and J. C. Horvath: Human natural killer cells: a comprehensive review. Int J Oncol 27, 5-4, (2005)
79. C. C. Chang and S. Ferrone: NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol 16, 383-392 (2006)
80. R. Mocikat, H. Braumuller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch, A. Bubek, J. Louis, R. Mailhammer, G. Riethmuller, U. Koszinowski and M. Röcken: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561-569 (2003)
81. K. P. Kane, K. J. Lavender and B. J. Ma: Ly-49 receptors and their functions. Crit Rev Immunol. 24, 321-348 (2004)
82. O. Ashiru, P. Boutet, L. Fernández-Messina, S. Agüera- González, J. N. Skepper, M. Valés-Gómez and H. T. Reyburn: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 70, 481-489 (2010)
83. R. J. Boyton and D. M. Altmann: Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease Clin Exp Immunol 149, 1-8 (2007)
84. J. Wu and L. L. Lanier: Natural killer cells and cancer. Adv Cancer Res 90, 127-156 (2003)
85. R. Kim, M. Emi, K. Tanabe and K. Arihiro: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66, 5527-5536 (2006)
86. K. Elgert, D. Alleva and D. Mullins: Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64, 275-90 (1998)
87. C. Brigati, D. M. Noonan, A. Albini and R. Benelli: Tumor and inflammatory infiltrates: friends or foes? Clin Exp Meta 19, 247-258 (2002)
88. R. N. Apte, S. Dotan, M. Elkabets, M. R. White, E. Reich, Y. Carmi, X. Song, T. Dvozkin, Y. Krelin and E. Voronov: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25, 387-408 (2006)
89. M. J. Smyth: Type I interferon and cancer immunoediting. Nat Immunol 6, 646-648 (2005)
90. M. R. Shurin, G. V. Shurin, A. Lokshin, Z. R. Yurkovetsky, D. W. Gutkin, G. Chatta, H. Yhong, B. Han and R. Ferris: Intratumoral cytokines/chemokines/ growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25, 333-356 (2006)
91. K. E. de Visser, A. Eichten and L. M. Coussens: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37 (2006)
92. F. Salazar-Onfray, M. N. López and A. Mendoza- Naranjo: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18, 171-182 (2007)
93. P. Contini, M. Ghio, A. Poggi, G. Filaci, F. Indiveri, S. Ferrone and F. Puppo: Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33, 125-134 (2003)
94. T. L. Whiteside: The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36, 25-46 (2007)
95. M. J. Tisdale: Pathogenesis of cancer cachexia. J Support Oncol 1, 159-168 (2003)
96. A. Mantovani and F. Balkwill: RalB signaling: a bridge between inflammation and cancer. Cell 127, 42-44 (2006)
97. H. Yu, M. Kortylewski and D. Pardoll: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51 (2007)
98. J. J. Lee, Y. L. Chang, W. L. Lai, J. Y. Ko, M. Y. Kuo, C. P. Chiang, M. Azuma, C. W. Chen and J. S. Chia. Increased prevalence of interleukin-17- producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck. (2010) [Epub ahead of print]
99. A. F. Ochsenbein, P. Klenerman, U, Karrer, B. Ludewig, M. Pericin, H. Hengartner and R. M. Zinkernagel: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96, 2233-2238 (1999)
100. D. W. Kowalczyk: Tumors and danger model. Acta Bioch Pol 49, 295-302 (2002)
101. A. F. Ochsenbein: Immunological ignorance of solid tumors. Springer Semin Immunopathol 27, 19-35 (2005)
102. G. H. Sakorafas, E. Zouros and G. Peros: Applied vascular anatomy of the colon and rectum: clinical implications for the surgical oncologist. Surg Oncol 15, 243-255 (2006)
103. B. Bussolati, A. Ahmed, H. Pemberton, C. R. Landis, F. Di Carlo, D. O. Haskard and J. C. Mason: Bifunctional role for VEGF-induced heme oxigenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood 103, 761-766 (2004)
104. Y. Wu, M. Jin, H. Xu, Z. Shimin, S. He, L. Wang, Y. Zhang. Clinicopathologic significance of HIF-1- alpha, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol (2010)
105. L. Yang and D. P. Carbone: Tumor-host immune interactions and dendritic cell dysfunction. A dv Cancer Res 92, 13-27 (2004)
106. L. Stolze, A. K. Nussbaum, A. Sijts, N. P. Emmerich, P. M. Kloetzel and H. Schild: The function of the proteasome system in MHC class I antigen processing. Immunol Today 21, 317-319 (2000)
107. T. L. Whiteside: The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36, 25-46 (2007)
108. F . Ghiringhelli, C. Ménard, M. Terme, C. Flament, J. Taieb, N. Chaput, P. E. Puig, S. Novault, B. Escudier, E. Vivier, A. Lecesne, C. Robert, J. Y. Blay, J. Bernard, S. Caillat-Zucman, A. F reitas, T. Tursz, O. Wagner-Ballon, C. Capron, W. Vainchencker, F. Martin and L. Zitvogel: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202, 1075-1085 (2005)
109. M. Beyerand and J. L. Schulze: Regulatory T cells in cancer. Blood 108, 804-811 (2006)
110. J. Dannull, Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa and J. Vieweg: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115, 3623-3633 (2005)
111. E. Brillard, J. R. Pallandre, D. Chalmers, B. Ryffel, A. Radlovic, E. Seilles, P. S. Rohrlich, X. Pivot, P. Tiberghien, P. Saas and C. Borg: Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes. Exp Hematol 35, 416-425 (2007)
112. Y. Liu, S. Amarnath and W. Chen: Requirement of CD28 signaling in homeostasis/survival of TGF-beta converted CD4+CD25+ Tregs from thymic CD4+CD25- single positive T cells. Transplantation 82, 953-964 (2006)
113. J. Galon, W. H. Fridman and F. Pagès: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67, 1883-1886 (2007)
114. K. Uno, K. Okuno, T. Kato, S. Tada-Oikawa, N. Kan, H. Saotome, K. Yagi and J. Hamuro: Pre-operative intracellular glutathione levels of peripheral monocytes as a biomarker to predict survival of colorectal cancer patients. Cancer Immunol Immunother 59, 1457-1465 (2010)
115. B. Mlecnik, M. Tosolini, P. Charoentong, A. Kirilovsky, G. Bindea, A. Berger, M. Camus, M. Gillard, P. Bruneval, W. H. Fridman, F. Pagès, Z. Trajanoski and J. Galon: Biomolecular network reconstruction identifies Tcell homing factors associated with survival in colorectal cancer. Gastroenterology 138, 1429-1440 (2010)